ReviewImmunologic research2026
Subcutaneous Sweet Syndrome as an uncommon mucocutaneous manifestation in systemic lupus erythematosus: a case report and literature review.
Review in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Sweet Syndrome (SS) as a mucocutaneous manifestation of systemic lupus erythematosus (SLE) has been rarely reported in the literature. The subcutaneous variant of SS in SLE patients is extremely rare. We present a case of a subcutaneous SS occurring as a manifestation of SLE and we discuss the findings reported in the literature regarding this association. The patient was a 31-year-old woman with a recently diagnosis of SLE. On admission she presented with malaise, fever, and skin lesions consisting with tender and warmth large plaques with a violaceous erythema on the right thigh. Laboratory studies showed leukocytosis, neutrophilia, elevated high-sensitive C-reactive protein, hypocomplementemia and increased levels of anti-dsDNA. Others differential diagnosis were ruled out. The skin biopsy revealed a superficial and deep perivascular and periadnexal infiltrate, with neutrophils surrounding adipocytes, concluding the diagnosis of subcutaneous SS. She had a good response to treatment with prednisone 0.5 mg/kg/day, and dapsone 100 mg/day. A structured literature search was performed in PubMed, Web of Science and Scopus, identifying 17 published cases of SS associated with SLE. SS in SLE tends to occur early in the disease course and typically presents as painful violaceous erythematous plaques, accompanied by constitutional SLE manifestations and elevated anti-dsDNA and anti-Sm levels. SS should be considered as a possible manifestation in SLE patients.
Indexed as
Identifiers
41945165What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.